Success stops drug trial
Researchers said Tuesday that an experimental drug from Bristol-Myers Squibb and Pfizer reduces the risk of stroke by more than 50 percent compared to aspirin. The findings boost expectations for apixaban, a new anticoagulant pill that aims to displace the old, problematic heart drug warfarin as a prevention for stroke in patients with atrial fibrillation (AF). The race to find a drug that can replace warfarin, which was originally developed as a rat poison, could be worth billions of dollars annually, possibly as much as $20 billion, according to industry analysts. Boehringer Ingelheim, German maker of Pradaxa, is leading the race, awaiting a review by US regulatory advisors on September 20. But heart specialists meeting in Stockholm said a clear winner had yet to emerge. Stuart Connolly of McMaster University in Canada, who presented the findings on apixaban to the European Society of Cardiology, said the results with apixaban were ?truly impressive.? An AVERROES study of 5,600 patients was halted in June a
Success stops drug trial
The data monitoring committee of the AVERROES study, seeing overwhelming evidence of the success of apixaban in the prevention of stroke in patients with atrial fibrillation who are unsuitable ...
Tue 31 Aug 10 from PhysOrg
Success stops drug trial: Apixaban prevents stroke in patients with atrial fibrillation who are unsuitable for warfarin, Thu 2 Sep 10 from ScienceDaily
Success Stops Drug Trial, Tue 31 Aug 10 from RedOrbit
Success stops drug trial, Tue 31 Aug 10 from R&D Mag
Success stops drug trial, Tue 31 Aug 10 from e! Science News
Study shows local standards of care affect the benefits of switching to new treatement alternatives
An analysis of a trial into how a new drug dabigatran was effective in preventing stroke in patients with atrial fibrillation has shown that local standards of care affect the benefits of switching ...
Sun 29 Aug 10 from PhysOrg
Drug cuts stroke risk by half vs aspirin: study
STOCKHOLM (Reuters) - An experimental drug from Bristol-Myers Squibb and Pfizer reduces the risk of stroke by more than half compared with aspirin, with no significant rise in major bleeding, ...
Tue 31 Aug 10 from Reuters
New Anticlotting Drugs in the Works
The drugs apixaban and Xarelto are effective at preventing deadly blood clots, new studies show.
Wed 1 Sep 10 from WebMD
New Stroke Drug Apixaban Effective, Study Stopped
Tue 31 Aug 10 from Emaxhealth
Drug Works Better Than Aspirin In Lowering Stroke Risk
Researchers said Tuesday that an experimental drug from Bristol-Myers Squibb and Pfizer reduces the risk of stroke by more than 50 percent compared to aspirin. The findings boost expectations ...
Wed 1 Sep 10 from RedOrbit
Total number of sources: 12
Bookmark
